Galmed Pharmaceuticals Ltd.(GLMD)Earnings, Financials & Key Ratios
GLMD•NASDAQ
$0.63
$1M mkt cap·Price updated May 6, 2026
AboutGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Show more
- Revenue$0
- EBITDA-$6M-182.3%
- Net Income-$8M-8.8%
- EPS (Diluted)-8.08+73.0%
- ROE-49.77%+1.7%
- ROIC-41.42%-183.0%
- Interest Coverage-418.53-161.5%
GLMD Key Insights
Galmed Pharmaceuticals Ltd. (GLMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GLMD Price & Volume
Galmed Pharmaceuticals Ltd. (GLMD) stock price & volume — 10-year historical chart
Loading chart...
GLMD Growth Metrics
Galmed Pharmaceuticals Ltd. (GLMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-48.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2412%
Return on Capital
10 Years-48.65%
5 Years-41.39%
3 Years-22.22%
Last Year-41.57%
GLMD Peer Comparison
Galmed Pharmaceuticals Ltd. (GLMD) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKBA | 392.83M | 1.48 | -74 | 47.46% | -2.26% | -16.39% | ||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 CPRX | 3.74B | 30.52 | 18.17 | 19.78% | 36.39% | 22.46% | 0.00 | |
 GNFT | 447.53M | 8.95 | 256.88 | 134.56% | -14.12% | -22.98% | 0.90 | |
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 |
Compare GLMD vs Peers
Galmed Pharmaceuticals Ltd. (GLMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GLMD Income Statement
Galmed Pharmaceuticals Ltd. (GLMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 467K | 1.08M | 2.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | 132.33% | 87.83% | -100% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 35K | 39K | 42K | 35K | 31K | 83K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 467K▲ 0% | 1.08M▲ 132.3% | 2.04M▲ 87.8% | -35K▼ 101.7% | -39K▼ 11.4% | -42K▼ 7.7% | -35K▲ 16.7% | -31K▲ 11.4% | -83K▼ 167.7% | 0▲ 0% |
| Gross Margin % | 100% | 100% | 100% | - | - | - | - | - | - | - |
| Gross Profit Growth % | 1034% | 132.33% | 87.83% | -101.72% | -11.43% | -7.69% | 16.67% | 11.43% | -167.74% | - |
| Operating Expenses | 17.35M | 13.45M | 12.75M | 22.38M | 30.21M | 32.88M | 17.65M | -7.49M | 6.2M | 7.03M |
| OpEx % of Revenue | 3714.99% | 1239.54% | 625.76% | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.08M | 3.8M | 4.44M | 4.2M | 4.13M | 5.66M | 4.66M | 3.92M | 3.3M | 3.53M |
| SG&A % of Revenue | 659.1% | 350.14% | 217.86% | - | - | - | - | - | - | - |
| Research & Development | 14.27M | 9.65M | 8.31M | 18.18M | 26.08M | 27.22M | 12.99M | 3.57M | 2.98M | 3.5M |
| R&D % of Revenue | 3055.89% | 889.4% | 407.9% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.98M | -83K | 0 |
| Operating Income | -16.88M▲ 0% | -12.36M▲ 26.8% | -10.71M▲ 13.3% | -22.38M▼ 108.8% | -30.21M▼ 35.0% | -32.88M▼ 8.8% | -17.65M▲ 46.3% | 7.49M▲ 142.4% | -6.28M▼ 183.8% | -6.95M▲ 0% |
| Operating Margin % | -3614.99% | -1139.54% | -525.76% | - | - | - | - | - | - | - |
| Operating Income Growth % | -55.24% | 26.76% | 13.34% | -108.83% | -35.01% | -8.84% | 46.32% | 142.45% | -183.8% | - |
| EBITDA | -16.71M | -12.13M | -10.33M | -22.34M | -30.17M | -32.84M | -17.62M | 7.52M | -6.2M | -5.38M |
| EBITDA Margin % | -3578.8% | -1117.51% | -506.77% | - | - | - | - | - | - | - |
| EBITDA Growth % | -54.39% | 27.45% | 14.82% | -116.31% | -35.05% | -8.84% | 46.36% | 142.71% | -182.35% | 12.26% |
| D&A (Non-Cash Add-back) | 169K | 239K | 387K | 35K | 39K | 42K | 35K | 31K | 83K | 1.56M |
| EBIT | -16.88M | -12.36M | -10.71M | -22.38M | -30.21M | -32.88M | -17.65M | -6.9M | -7.5M | -8.59M |
| Net Interest Income | 315K | 153K | 917K | 1.88M | 1.16M | 519K | 82K | 364K | 488K | -51K |
| Interest Income | 35K | 65K | 959K | 1.92M | 1.19M | 562K | 297K | 375K | 503K | 397K |
| Interest Expense | 67K | 49K | 42K | 33K | 31K | 43K | 215K | 11K | 15K | 448K |
| Other Income/Expense | 35K | 65K | 934K | 1.92M | 1.44M | 414K | -215K | -14.4M | -1.24M | -1.77M |
| Pretax Income | -16.85M▲ 0% | -12.3M▲ 27.0% | -9.78M▲ 20.5% | -20.46M▼ 109.2% | -28.77M▼ 40.6% | -32.47M▼ 12.8% | -17.87M▲ 45.0% | -6.91M▲ 61.3% | -7.52M▼ 8.8% | -8.72M▲ 0% |
| Pretax Margin % | -3607.49% | -1133.55% | -479.93% | - | - | - | - | - | - | - |
| Income Tax | 106K | 0 | 75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.63% | 0% | -0.77% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -16.95M▲ 0% | -12.3M▲ 27.5% | -9.86M▲ 19.9% | -18.54M▼ 88.1% | -27.61M▼ 48.9% | -31.95M▼ 15.7% | -18.57M▲ 41.9% | -6.91M▲ 62.8% | -7.52M▼ 8.8% | -8.72M▲ 0% |
| Net Margin % | -3630.19% | -1133.55% | -483.61% | - | - | - | - | - | - | - |
| Net Income Growth % | -59.6% | 27.45% | 19.86% | -88.12% | -48.91% | -15.71% | 41.87% | 62.78% | -8.75% | -48.26% |
| Net Income (Continuing) | -16.95M | -12.3M | -9.86M | -20.46M | -28.77M | -32.47M | -17.87M | -6.91M | -7.52M | -8.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -22.36▲ 0% | -14.77▲ 33.9% | -8.15▲ 44.8% | -13.17▼ 61.6% | -19.46▼ 47.8% | -19.48▼ 0.1% | -11.08▲ 43.1% | -29.95▼ 170.3% | -8.08▲ 73.0% | -2.21▲ 0% |
| EPS Growth % | -55.82% | 33.94% | 44.82% | -61.6% | -47.76% | -0.1% | 43.12% | -170.31% | 73.02% | -2412% |
| EPS (Basic) | -22.36 | -14.77 | -8.15 | -13.17 | -19.46 | -19.48 | -11.08 | -30.05 | -8.08 | - |
| Diluted Shares Outstanding | 758.31K | 832.49K | 1.21M | 1.41M | 1.42M | 1.64M | 1.68M | 230.79K | 930.82K | 3.95M |
| Basic Shares Outstanding | 758.31K | 832.49K | 1.21M | 1.41M | 1.42M | 1.64M | 1.68M | 230K | 930.82K | 3.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GLMD Balance Sheet
Galmed Pharmaceuticals Ltd. (GLMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.73M | 19.15M | 90.41M | 76.43M | 51.81M | 36.05M | 14.72M | 13.24M | 16.12M | 21.08M |
| Cash & Short-Term Investments | 15.45M | 19M | 90.19M | 75.49M | 50.89M | 34.81M | 13.79M | 12.64M | 15.33M | 20.53M |
| Cash Only | 3.1M | 13.02M | 24.16M | 15.93M | 6.95M | 2.88M | 2.02M | 2.86M | 4.65M | 4.96M |
| Short-Term Investments | 12.35M | 5.98M | 66.03M | 59.56M | 43.94M | 31.93M | 11.77M | 9.78M | 10.68M | 15.56M |
| Accounts Receivable | 284K | 155K | 51K | 226K | 66K | 79K | 0 | 165K | 209K | 433K |
| Days Sales Outstanding | 221.97 | 52.14 | 9.13 | - | - | - | - | - | - | - |
| Inventory | -254K | -100K | 0 | 0 | 0 | 0 | 114K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | 1.19K | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 112K | 113K | 114K | 0 | 117K | 121K | 123K |
| Total Non-Current Assets | 718K | 491K | 194K | 709K | 570K | 551K | 1.84M | 3.39M | 2.38M | 1.86M |
| Property, Plant & Equipment | 718K | 491K | 194K | 709K | 570K | 551K | 337K | 125K | 0 | 0 |
| Fixed Asset Turnover | 0.65x | 2.21x | 10.51x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.5M | 3.27M | 2.12M | 9.1M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 257K | 791K |
| Total Assets | 16.45M▲ 0% | 19.64M▲ 19.4% | 90.6M▲ 361.2% | 77.14M▼ 14.9% | 52.38M▼ 32.1% | 36.6M▼ 30.1% | 16.56M▼ 54.8% | 16.63M▲ 0.4% | 18.5M▲ 11.3% | 22.94M▲ 0% |
| Asset Turnover | 0.03x | 0.06x | 0.02x | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -32.2% | 19.41% | 361.23% | -14.86% | -32.1% | -30.12% | -54.76% | 0.41% | 11.25% | 130.68% |
| Total Current Liabilities | 4.58M | 3.85M | 2.71M | 6.93M | 8.01M | 5.88M | 3.09M | 2.75M | 2.17M | 2.42M |
| Accounts Payable | 3.12M | 2.28M | 1.81M | 6M | 7.05M | 4.87M | 2.56M | 1.88M | 1.31M | 1.37M |
| Days Payables Outstanding | - | - | - | 62.56K | 65.94K | 42.33K | 26.7K | 22.12K | 5.75K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1.09M | 538K | 0 | 0 | 0 | 0 | -171K | 0 | 0 | 0 |
| Other Current Liabilities | 363K | 1.03M | 892K | 935K | 966K | 1.01M | 363K | 571K | 603K | 0 |
| Current Ratio | 3.44x | 4.98x | 33.41x | 11.02x | 6.47x | 6.13x | 4.76x | 4.81x | 7.42x | 7.42x |
| Quick Ratio | 3.49x | 5.00x | 33.41x | 11.02x | 6.47x | 6.13x | 4.72x | 4.81x | 7.42x | 7.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 796K | 0 | 0 | 352K | 216K | 229K | 44K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 352K | 216K | 229K | 44K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 267K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.38M | 3.85M | 2.71M | 7.29M | 8.23M | 6.11M | 3.14M | 2.75M | 2.17M | 2.42M |
| Total Debt | 0 | 0 | 0 | 352K | 216K | 229K | 44K | 41K | 0 | 0 |
| Net Debt | -3.1M | -13.02M | -24.16M | -15.58M | -6.73M | -2.65M | -1.97M | -2.82M | -4.65M | -4.96M |
| Debt / Equity | - | - | - | 0.01x | 0.00x | 0.01x | 0.00x | 0.00x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.01x | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.37x | - | 0.92x |
| Interest Coverage | -251.97x | -252.33x | -255.12x | -678.06x | -974.52x | -764.67x | -82.10x | 681.09x | -418.53x | -19.18x |
| Total Equity | 11.07M▲ 0% | 15.79M▲ 42.6% | 87.89M▲ 456.5% | 69.85M▼ 20.5% | 44.15M▼ 36.8% | 30.5M▼ 30.9% | 13.42M▼ 56.0% | 13.88M▲ 3.4% | 16.33M▲ 17.6% | 20.52M▲ 0% |
| Equity Growth % | -48.6% | 42.62% | 456.47% | -20.53% | -36.79% | -30.93% | -55.99% | 3.4% | 17.64% | 142.64% |
| Book Value per Share | 14.60 | 18.97 | 72.69 | 49.62 | 31.12 | 18.60 | 8.01 | 60.14 | 17.54 | 5.20 |
| Total Shareholders' Equity | 11.07M | 15.79M | 87.89M | 69.85M | 44.15M | 30.5M | 13.42M | 13.88M | 16.33M | 20.52M |
| Common Stock | 34K | 40K | 58K | 58K | 58K | 70K | 70K | 209K | 742K | 2.69M |
| Retained Earnings | -64.32M | -76.62M | -86.47M | -106.94M | -135.71M | -168.17M | -186.04M | -192.95M | -200.47M | -204.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -85K | -7K | -11K | 35K | 272K | -171K | -745K | -454K | -416K | -403K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GLMD Cash Flow Statement
Galmed Pharmaceuticals Ltd. (GLMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.13M | -12.07M | -9.02M | -14.94M | -26.29M | -32.89M | -18.5M | -6.14M | -5.88M | -5.88M |
| Operating CF Margin % | -2597.22% | -1112.17% | -442.74% | - | - | - | - | - | - | - |
| Operating CF Growth % | -43.13% | 0.51% | 25.23% | -65.54% | -75.99% | -25.13% | 43.75% | 66.83% | 4.19% | -56.59% |
| Net Income | -16.95M | -12.3M | -9.86M | -20.46M | -28.77M | -32.47M | -17.87M | -6.91M | -7.52M | -8.72M |
| Depreciation & Amortization | 169K | 239K | 387K | 35K | 39K | 42K | 35K | 31K | 83K | 0 |
| Stock-Based Compensation | 1.63M | 1.39M | 1.78M | 2.23M | 2.07M | 1.89M | 1.3M | 892K | 531K | 449K |
| Deferred Taxes | -1.4M | 164K | 12K | -114K | -437K | 84K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.67M | -167K | -144K | -63K | -285K | 13K | 485K | -280K | 1.75M | 2.23M |
| Working Capital Changes | 2.75M | -1.4M | -1.21M | 3.44M | 1.1M | -2.45M | -2.45M | 132K | -728K | 576K |
| Change in Receivables | 95K | 129K | -63K | -609K | 15K | -313K | 300K | 345K | -192K | -298K |
| Change in Inventory | 81K | 671K | -142K | 609K | -15K | 313K | -300K | 0 | 0 | 0 |
| Change in Payables | 863K | -846K | -462K | 4.18M | 1.05M | -2.17M | -2.31M | -681K | -571K | 166K |
| Cash from Investing | 6.34M | 6.44M | -60.02M | 6.68M | 16.54M | 11.46M | 17.56M | 800K | -1.11M | -7.74M |
| Capital Expenditures | -17K | -21K | -90K | -12K | -44K | -11K | -4K | 0 | 0 | 0 |
| CapEx % of Revenue | 3.64% | 1.94% | 4.42% | - | - | - | - | - | - | - |
| Acquisitions | 13K | 0 | 6.08M | 21.8M | -24.94M | 0 | -17.57K | -1.5M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 13K | 9K | -6.08M | -21.8M | 24.94M | -1K | 17.57K | 0 | -250K | -250K |
| Cash from Financing | 4.73M | 15.55M | 80.18M | 143K | 768K | 17.37M | 70K | 6.18M | 8.79M | 16.34M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | 707K | 1000K | 70K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 255K | 530K | 1.03M | 143K | 61K | 0 | 0 | 0 | 0 | 3.94M |
| Net Change in Cash | -1.06M▲ 0% | 9.92M▲ 1037.1% | 11.14M▲ 12.2% | -8.12M▼ 172.9% | -8.98M▼ 10.7% | -4.06M▲ 54.8% | -868K▲ 78.6% | 848K▲ 197.7% | 1.79M▲ 111.7% | 3.13M▲ 0% |
| Free Cash Flow | -12.15M▲ 0% | -12.09M▲ 0.5% | -9.11M▲ 24.6% | -14.95M▼ 64.0% | -26.33M▼ 76.1% | -32.9M▼ 25.0% | -18.5M▲ 43.8% | -6.14M▲ 66.8% | -5.88M▲ 4.2% | -5.47M▲ 0% |
| FCF Margin % | -2600.86% | -1114.1% | -447.15% | - | - | - | - | - | - | - |
| FCF Growth % | -40.69% | 0.48% | 24.61% | -64.04% | -76.14% | -24.96% | 43.76% | 66.84% | 4.19% | 7.67% |
| FCF per Share | -16.02 | -14.52 | -7.54 | -10.62 | -18.56 | -20.06 | -11.04 | -26.59 | -6.32 | -6.32 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.98x | 0.92x | 0.81x | 0.95x | 1.03x | 1.00x | 0.89x | 0.78x | 0.63x |
| Interest Paid | 382K | 0 | 865K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 106K | 0 | 75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GLMD Key Ratios
Galmed Pharmaceuticals Ltd. (GLMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -103.94% | -91.54% | -19.01% | -23.51% | -48.44% | -85.59% | -84.57% | -50.63% | -49.77% | -42.5% |
| Return on Invested Capital (ROIC) | -99.83% | -172.49% | -24.17% | -28.44% | -49.42% | -75.57% | -67.38% | 49.92% | -41.42% | -41.42% |
| Gross Margin | 100% | 100% | 100% | - | - | - | - | - | - | - |
| Net Margin | -3630.19% | -1133.55% | -483.61% | - | - | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.01x | 0.00x | 0.01x | 0.00x | 0.00x | - | 0.00x |
| Interest Coverage | -251.97x | -252.33x | -255.12x | -678.06x | -974.52x | -764.67x | -82.10x | 681.09x | -418.53x | -19.18x |
| FCF Conversion | 0.72x | 0.98x | 0.92x | 0.81x | 0.95x | 1.03x | 1.00x | 0.89x | 0.78x | 0.63x |
| Revenue Growth | - | 132.33% | 87.83% | -100% | - | - | - | - | - | - |
GLMD Frequently Asked Questions
Galmed Pharmaceuticals Ltd. (GLMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Galmed Pharmaceuticals Ltd. (GLMD) grew revenue by 0.0% over the past year. Growth has been modest.
Galmed Pharmaceuticals Ltd. (GLMD) reported a net loss of $8.7M for fiscal year 2024.
Dividend & Returns
Galmed Pharmaceuticals Ltd. (GLMD) has a return on equity (ROE) of -49.8%. Negative ROE indicates the company is unprofitable.
Galmed Pharmaceuticals Ltd. (GLMD) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More GLMD
Galmed Pharmaceuticals Ltd. (GLMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates